Search

Your search keyword '"Hornung, Joachim"' showing total 12 results
Start Over Author "Hornung, Joachim" Publication Year Range This year
12 results on '"Hornung, Joachim"'

1. Safety and performance of the new med-el total ossicular replacement prostheses

Author

Schimanski, Esther, Lenarz, Thomas, Busch, Susan, Arndt, Susan, Offergeld, Christian, Arnoldner, Christoph, Riss, Dominik, Hornung, Joachim, Taha, Lava, Zwittag, Paul Martin, Rubicz, Nina, Beutner, Dirk, Bevis, Nicholas, Loader, Benjamin, Windisch, Franz, Sprinzl, Georg, Magele, Astrid, Wolfram, Wendelin, Niederwanger, Lisa, Plichta, Łukasz, and Skarżyński, Piotr H.

Published
2024
Full Text
View/download PDF

2. Short-term safety and effectiveness of the mCLIP partial prosthesis

Author

Rasse, Thomas, Niederwanger, Lisa, Hornung, Joachim, Taha, Lava, Arndt, Susan, Offergeld, Christian, Beutner, Dirk, Bevis, Nicholas, Lenarz, Thomas, Teschner, Magnus, Schimanski, Esther, Georg Sprinzl, Magele, Astrid, Skarżyński, Piotr H., Plichta, Łukasz, Arnoldner, Christoph, Riss, Dominik, Loader, Benjamin, Windisch, Franz, Rubicz, Nina, and Zwittag, Paul Martin

Published
2024
Full Text
View/download PDF

11. Surgical Versus Noninvasive Manual Repositioning After Cochlear Implant Partial Magnet Dislocation

Author

Rupp, Robin, Balk, Matthias, Allner, Moritz, Sievert, Matti, Mueller, Sarina K., Hoppe, Ulrich, Hornung, Joachim, Iro, Heinrich, and Gostian, Antoniu-Oreste

Abstract

Objectives:To compare surgical magnet repositioning (SMR) and noninvasive manual magnet repositioning (MMR) as treatments for partial magnet dislocation (PMD) of the internal magnet in a cochlear implant (CI) caused by magnetic resonance imaging (MRI). The primary objective was the success rate, while the secondary objectives were total postinterventional CI downtime and complications. Methods:This single-center retrospective study was conducted at a tertiary referral medical center. Patients with CI treated for PMD between January 1, 2007 and September 30, 2022 were included. SMR served as primary treatment until June 2019 and as secondary treatment after the introduction of MMR. Results:A total of 51 cases of PMD were observed in 42 patients and 43 devices (18 ♀; 24 ♂; 12 with bilateral CI). MMR was performed successfully in 19 out of 20 cases (95%), while 32 cases were managed successfully by SMR. The median age at first magnet repositioning was 53.8 years (minimum 19 years, maximum 93 years). When MMR was performed, the mean time from diagnosis to treatment (0.5 ± 1.5 days vs 9.8 ± 7.6 days; P< .01), the mean time from repositioning to CI reactivation (1.4 ± 4.3 days vs 13.1 ± 6.7 days; P< .01), and the mean total CI downtime (1.9 ± 4.8 days vs 22.9 ± 11.9 days; P< .01) were significantly shorter compared to SMR. Significantly fewer complications were experienced with MMR [n= 0 (0%) vs n= 8 (25%); P= .04]. Conclusion:In case of PMD caused by MRI, noninvasive MMR shows a high success rate with a shorter total CI downtime as well as a lower complication rate compared to SMR. Therefore, MMR should be considered as first line treatment with SMR as a second option in case of failure.

Published
2024
Full Text
View/download PDF

12. High-Dose Glucocorticoids for the Treatment of Sudden Hearing Loss.

Author

Plontke SK, Girndt M, Meisner C, Fischer I, Böselt I, Löhler J, Ludwig-Kraus B, Richter M, Steighardt J, Reuter B, Böttcher C, Langer J, Pethe W, Seiwerth I, Jovanovic N, Großmann W, Kienle-Gogolok A, Boehm A, Neudert M, Diensthuber M, Müller A, Dazert S, Guntinas-Lichius O, Hornung J, Vielsmeier V, Stadler J, and Rahne T

Subjects
Adult, Humans, Dexamethasone, Prednisone, Treatment Outcome, Glucocorticoids, Hearing Loss, Sudden chemically induced
Abstract

BACKGROUND: Systemic glucocorticoids are commonly used for primary therapy of idiopathic sudden sensorineural hearing loss (ISSNHL). However, the comparative effectiveness and risk profiles of high-dose over lower-dose regimens remain unknown. METHODS: We randomly assigned patients with sudden hearing loss of greater than or equal to 50 dB within 7 days from onset to receive either 5 days of high-dose intravenous prednisolone at 250 mg/d (HD-Pred), 5 days of high-dose oral dexamethasone at 40 mg/d (HD-Dex), or, as a control, 5 days of oral prednisolone (Pred-Control) at 60 mg/d followed by 5 days of tapering doses. The primary outcome was the change in hearing threshold (pure tone average) in the three most affected contiguous frequencies from baseline to day 30. Secondary outcomes included speech understanding, tinnitus, communication competence, quality of life, hypertension, and insulin resistance. RESULTS: A total of 325 patients were randomly assigned. Mean change in 3PTAmost affected hearing threshold from baseline to 30 days was 34.2 dB (95% CI, 28.4 to 40.0) in the HD-Pred group, 41.4 dB (95% CI, 35.6 to 47.2) in the HD-Dex group, and 41.0 dB (95% CI, 35.2 to 46.8) in the Pred-Control group (P=0.09 for analysis of variance). There were more adverse events related to trial medication in the HD-Pred (n=73) and HD-Dex (n=76) groups than in the Pred-Control group (n=46). CONCLUSIONS: Systemic high-dose glucocorticoid therapy was not superior to a lower-dose regimen in patients with ISSNHL, and it was associated with a higher risk of side effects. (Funded by the Federal Ministry of Education and Research [BMBF]; EudraCT number, 2015‐002602‐36.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results